Does Medicare Part D Cover Ocrevus?
Yes — Ocrevus (Ocrelizumab) is covered under Medicare Part D, filled by 62,000 beneficiaries across 148,000 claims in the latest year. It typically sits on tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000.
Ocrevus Medicare Coverage & Out-of-Pocket Cost
Ocrevus is covered under Medicare Part D, with the program paying an average of $23,635 per prescription fill. Ocrevus typically falls on Tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000.
Your actual out-of-pocket cost depends on three factors: (1) formulary tier — your plan's specific placement; (2) deductible status — most plans require you to meet up to a $590 deductible (2025) before copays kick in; (3) coverage phase — initial coverage, then the donut hole was eliminated in 2025, replaced by a hard $2,000 annual out-of-pocket cap under the Inflation Reduction Act. Once you hit $2,000 in true out-of-pocket spending, the rest of your Part D drugs are free for the year.
Because generic Ocrelizumab is available, the single biggest savings move is asking your pharmacist about generic substitution. Generics typically sit on Tier 1 with copays under $10, vs Tier 2-3 placement for brand-name Ocrevus. Most states allow automatic substitution unless your prescriber writes "dispense as written."
For cash-pay or commercial insurance scenarios, compare prices using GoodRx, SingleCare, or Cost Plus Drugs before filling — discount-program prices sometimes beat Part D copays for lower-cost generics.
How to Confirm Ocrevus Coverage & Handle a Denial
Medicare Part D coverage of Ocrevus is set plan-by-plan, not nationally. To confirm your plan covers it, look up Ocrevus in the Medicare Plan Finder or your plan's online drug list, and check three flags: the formulary tier (drives your copay), prior authorization (PA), and step therapy (ST) or quantity limits.
Because Ocrevus is a higher-cost drug, plans are more likely to require prior authorization or step therapy — meaning you may need to try a lower-cost alternative first, or your prescriber must document why Ocrevus is medically necessary. If your plan denies coverage, you have the right to a formulary exception: your prescriber submits a statement of medical necessity, and the plan must respond within 72 hours (24 hours if expedited).
A denial can be appealed through five levels — redetermination by the plan, an independent review entity, an Administrative Law Judge, the Medicare Appeals Council, and finally federal court. Coverage resets every January, so re-check Ocrevus on your formulary during open enrollment (October 15 – December 7) even if it was covered this year.
Key Facts: Ocrevus Cost
- Medicare Part D avg
- $23,635/claim
- Likely Part D tier
- Tier 4-5 (specialty)
- Annual cost/patient
- $56,419
- Generic available
- Yes — Ocrelizumab
- Manufacturer
- Genentech/Roche
- Treats
- Multiple Sclerosis
- YoY price change
- +16.5%
Source: CMS Medicare Part D Spending Dashboard. Tier placement inferred from typical formulary norms — confirm with your specific Part D plan.
Ocrevus is manufactured by Genentech/Roche and prescribed primarily for Multiple Sclerosis. In the most recent Medicare Part D data, 148,000 claims were filed for 62,000 unique beneficiaries, at an average cost of $23,635 per claim. Average annual cost per beneficiary is $56,419.
Year over year, Medicare spending on Ocrevus has increased by +16.5%. Because a generic version of Ocrelizumab is available, patients can often substitute to reduce out-of-pocket costs. Its patent expires 2023-01-31.
Ocrevus belongs to the Multiple Sclerosis (MS) Treatments class. B-cell depleting therapies (Ocrevus, Kesimpta) destroy B-cells that attack myelin. S1P receptor modulators (Gilenya, oral) trap white blood cells in lymph nodes. Fumarates (Tecfidera) have anti-inflammatory and neuroprotective effects. Interferons (older DMTs) modulate the immune response. Each mechanism targets a different part of the immune system's attack on the nervous system.
Key Data
| Metric | Value |
|---|---|
| Avg Cost Per Claim | $23,635 |
| Total Medicare Spending | $3498.0M |
| Total Claims | 148,000 |
| Beneficiaries | 62,000 |
| Generic Available | Yes |
| Year-Over-Year Change | +16.5% |
Other Drugs for Multiple Sclerosis
Frequently Asked Questions
Yes. Ocrevus appears in Medicare Part D claims data, with 62,000 beneficiaries filling 148,000 prescriptions in the latest year. Whether your specific plan covers it depends on that plan's formulary, so confirm on your plan's Summary of Benefits.
It can. Many Part D plans apply prior authorization, step therapy, or quantity limits to Ocrevus — higher-cost drugs like this one are the most likely to carry these requirements. Prior authorization means your prescriber must document medical necessity before the plan pays. Check your plan's formulary "PA," "ST," or "QL" flags, or ask your pharmacist to run a test claim.
You have appeal rights. Start with a coverage determination / formulary exception request from your plan (your prescriber submits a supporting statement). If denied, you can escalate through five levels: redetermination, an independent review entity, an Administrative Law Judge, the Medicare Appeals Council, and federal court. Expedited 72-hour decisions are available when waiting could jeopardize your health.
Most Medicare Advantage plans include Part D drug coverage (MA-PD), so Ocrevus is generally available — but each Advantage plan sets its own formulary, tier, and pharmacy network. Coverage and copay can differ from Original Medicare plus a standalone Part D plan, so compare the specific plan's drug list before enrolling.
Ocrevus is typically placed on Tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000. Your exact tier and cost-sharing are set by your individual plan and can change each plan year.
Use the Medicare Plan Finder at medicare.gov, enter Ocrevus, and review each plan's formulary, tier, and restrictions. You can also call the number on your insurance card or check the plan's online drug lookup. Coverage is reset every January, so re-check during open enrollment (Oct 15 – Dec 7).
More about Ocrevus
Yes — Ocrevus (Ocrelizumab) is covered under Medicare Part D, filled by 62,000 beneficiaries across 148,000 claims in the latest year. It typically sits on tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000.
This answer pulls from CMS Medicare Part D Drug Spending data, the authoritative federal source for U.S. Medicare prescription-drug pricing. The headline number above is the direct answer; what follows is the additional context most readers need to use the answer for a real decision rather than just a fact lookup.
A practical caveat: the headline answer above reflects the most recent CMS Medicare Part D Drug Spending data vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.
Source: CMS Medicare Part D Spending, 2026.